News
AIM
--
0.00%
--
AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
Benzinga · 4d ago
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
GlobeNewswire · 4d ago
AIM ImmunoTech advances in Phase 1 study for COVID-19 therapy
Upon completion of the dosing of Cohort 1 in a Phase 1 trial evaluating the safety of Ampligen as an intranasal therapy, AIM ImmunoTech (AIM) is moving to the dose
Seekingalpha · 4d ago
DJ AIM ImmunoTech Completes Dosing of First Cohort in Covid-19 Treatment
Dow Jones · 4d ago
AIM ImmunoTech Announces Safety Data In First Cohort Of Phase 1 Clinical Study Investigating Intranasal Administration Of Ampligen As Potential Prophylaxis Or Treatment For COVID-19 And Other Respiratory Viral Diseases
AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, reporting no serious adverse events,
Benzinga · 4d ago
AIM ImmunoTech On Apr. 5 Approved Proposal From Polysciences For Manufacture Of AIM's Poly I And Poly C12U polynucleotides; Seperately Entered MArerial Transfer And Research Agreement With University of Cagliari Dipartimento di Scienze della Vita e dell'A
AIM ImmunoTech Inc. (“AIM” or “Company”) has recently entered into two agreements.   On April 5, 2021, the Company approved a proposal from Polysciences Inc. (“Polysciences”)
Benzinga · 4d ago
Sensors for Aircraft Market Research Report by Application, by Type, Global Forecast to 2027, Cumulative Impact of COVID-19
Market Insight Reports · 4d ago
Maxim Group Gives a Buy Rating to AIM ImmunoTech (AIM)
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to AIM ImmunoTech (AIM), with a price target of $5.00. The company's
SmarterAnalyst · 04/02 11:25
AIM ImmunoTech EPS misses by $0.02, misses on revenue
AIM ImmunoTech (AIM): FY GAAP EPS of -$0.45 misses by $0.02.Revenue of $0.16M (+14.3% Y/Y) misses by $0.31M.As of December 31, 2020, AIM had cash, cash equivalents and marketable securities
Seekingalpha · 03/31 14:39
AIM ImmunoTech Q4 EPS $(0.09) Up From $(0.33) YoY, Sales $42.00K Down From $50.00K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.09) per share. This is a 72.73 percent increase over losses of $(0.33) per share from the same period last year. The company reported $42.00 thousand in sales
Benzinga · 03/31 13:27
AIM ImmunoTech 2020 Loss/Shr 45c >AIM
AIM ImmunoTech 2020 Loss/Shr 45c >AIM
Dow Jones · 03/31 13:17
AIM ImmunoTech 2020 Rev $163,000 >AIM
AIM ImmunoTech 2020 Rev $163,000 >AIM
Dow Jones · 03/31 13:17
Press Release: AIM ImmunoTech Reports 2020 Year-End Financial Results
Dow Jones · 03/31 13:15
10-K: AIM IMMUNOTECH INC.
(EDGAR Online via COMTEX) -- ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 03/31 10:08
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Centers Ongoing Study in Cancer Patients with COVID-19
GlobeNewswire · 03/22 13:45
BRIEF-AIM Immunotech Announces Addition Of Single-Agent Ampligen Arm To Cancer Center’S Ongoing Study In Cancer Patients With Covid-19
reuters.com · 03/22 13:15
Aircraft Pitot Tubes Market Size 2021 Share, Global Companies, Consumption, Drivers, Top Leading Countries, Trends, Forces Analysis, Revenue, Challenges and Global Growth Forecast 2025
Mar 16, 2021 (The Expresswire) -- Global Aircraft Pitot Tubes Market Research report discusses the market growth drivers and challenges that the manufacturer...
The Express Wire · 03/16 05:32
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
GlobeNewswire · 03/11 12:00
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
OCALA, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIM’s Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M V...
GlobeNewswire · 03/10 11:55
Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education
- Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here
GlobeNewswire · 03/08 19:36
Webull provides a variety of real-time AIM stock news. You can receive the latest news about AIM ImmunoTech Inc through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.